Charles Fuchs, MD: Impeding RAS Mutation Testing
What are some issues that impede widespread adoption of recommended testing for RAS mutations?
The problem that goes on in the U.S. is the access to all RAS testing. A lot of hospitals and pathology laboratories may have access to technology that allows them to do just EXON 2 or CODONs 12 or 13 of KRAS, but might not be equipped to do all RAS testing. As a result, many centers have to do send-outs to commercial laboratories to get all RAS testing. I think that's the limiting step.
The other consideration is that it doesn't necessarily come back quickly. The result can take 2 weeks or long in certain circumstances to get all RAS sequence data from a laboratory. Many patients don't want to wait that long to start systemic therapy for metastatic colorectal cancer. As I mentioned, if you're having trouble getting back the result on RAS testing, it's perfectly reason to use your first line regimen of chemotherapy plus bevacizumab, and then once you get the RAS testing data, put that into your paradigm so that you might give an EGFR receptor in a second or third line for a RAS wild type patient.
Unresectable Colon Cancer: Case 2
52-year-old woman newly diagnosed with metastatic CRC and is genotyped as part of her initial work up.
Retrospective Data Demonstrates Efficacy of Regorafenib in mCRC
April 16th 2024During a Case-Based Roundtable® event, Madappa Kundranda, MD, PhD, discussed recent retrospective studies that compared outcomes between the available treatment options in patients with relapsed/refractory advanced colorectal cancer in the first article of a 2-part series.
Read More
Peritoneal RFS May Be a Stronger Predictor of OS in CRC Peritoneal Metastasis
March 27th 2024In an interview with Targeted Oncology, Muhammad Talha Waheed, MBBS, discussed research on the reliability of using recurrence-free survival as an efficacy end point for trials evaluating patients with colorectal cancer peritoneal metastasis.
Read More
Study Finds Susceptibility Gene Variations by Race/Ethnicity in Early-Onset CRC
February 20th 2024In an interview with Targeted Oncology, Andreana N. Holowatyj, PhD, MSCI, discussed data from a study which found racial and ethnic differences in susceptibility genes for early-onset colorectal cancer, suggesting current multigene panel tests may not be accurate for diverse populations.
Read More
